tiprankstipranks
Trending News
More News >
Photocure ASA (PHCUF)
OTHER OTC:PHCUF

Photocure ASA (PHCUF) Price & Analysis

Compare
9 Followers

PHCUF Stock Chart & Stats

$6.82
$0.17(3.46%)
At close: 4:00 PM EST
$6.82
$0.17(3.46%)

Photocure ASA News

PHCUF FAQ

What was Photocure ASA’s price range in the past 12 months?
Photocure ASA lowest stock price was $4.02 and its highest was $8.35 in the past 12 months.
    What is Photocure ASA’s market cap?
    Photocure ASA’s market cap is $184.65M.
      When is Photocure ASA’s upcoming earnings report date?
      Photocure ASA’s upcoming earnings report date is Feb 18, 2026 which is in 5 days.
        How were Photocure ASA’s earnings last quarter?
        Photocure ASA released its earnings results on Oct 29, 2025. The company reported $0.016 earnings per share for the quarter, beating the consensus estimate of -$0.007 by $0.023.
          Is Photocure ASA overvalued?
          According to Wall Street analysts Photocure ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Photocure ASA pay dividends?
            Photocure ASA does not currently pay dividends.
            What is Photocure ASA’s EPS estimate?
            Photocure ASA’s EPS estimate is -0.03.
              How many shares outstanding does Photocure ASA have?
              Photocure ASA has 27,120,820 shares outstanding.
                What happened to Photocure ASA’s price movement after its last earnings report?
                Photocure ASA reported an EPS of $0.016 in its last earnings report, beating expectations of -$0.007. Following the earnings report the stock price went up 1.304%.
                  Which hedge fund is a major shareholder of Photocure ASA?
                  Currently, no hedge funds are holding shares in PHCUF
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Photocure ASA

                    Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

                    Photocure ASA (PHCUF) Earnings & Revenues

                    PHCUF Company Deck

                    PHCUF Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The earnings call highlighted Photocure's strong product growth, strategic market expansions, and positive financial performance, despite challenges in the Flex segment and foreign exchange impacts. The company is well-positioned for future growth with innovative partnerships and a strong cash flow position.View all PHCUF earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Catalyst Pharma
                    Eagle Pharmaceuticals
                    Omeros
                    Tonix Pharma
                    Oncolytics Biotech
                    Pfizer

                    Ownership Overview

                    0.15%99.57%
                    Insiders
                    ― Other Institutional Investors
                    99.57% Public Companies and
                    Individual Investors

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks